Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Efficacy and Safety of Probiotics eN-Lac® Capsules (Lactobacillus Paracasei GMNL-32) for the Treatment of Children With Perennial Allergic Rhinitis

NCT01116778 is registered in ClinicalTrials.gov with GenMont Biotech Incorporation as lead sponsor.

NCT NCT01116778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01116778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Efficacy and Safety of Probiotics eN-Lac® Capsules (Lactobacillus Paracasei GMNL-32) for the Treatment of Children With Perennial Allergic Rhinitis
Lead sponsor
GenMont Biotech Incorporation
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2010
Completion date
June 30, 2012
Enrollment
236 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lactobacillus paracasei gmnl-32 (en-lac®), perennial allergic rhinitis, probiotics